1. The Nurse View: Hormone Receptor-Positive Advanced Breast Cancer

3. HR+ Advanced Breast Cancer Introduction

4. Restaging at Relapse vs De Novo Metastatic Disease

5. Visceral Crisis

6. Personalizing Endocrine Therapy

7. Endocrine Therapy Landscape

8. FIRST Trial Fulvestrant vs Anastrozole

9. FIRST Trial -- Safety

10. FALCON: Anastrozole vs Fulvestrant in HR+ Advanced or Metastatic Breast Cancer

11. FALCON Most Common AEs (> 5%)

12. Aromatase Inhibitors Management of AEs

13. HOPE Study Exercise Adherence

14. Overcoming Endocrine Resistance in MBC

15. PALOMA-2 Palbociclib + Letrozole vs Letrozole Alone

16. PALOMA-2 AE Summary

17. Palbociclib Dosing and Drug Interaction

18. Palbociclib Management of Hematological Toxicities

19. MONALEESA-2: Ribociclib + Letrozole vs Letrozole in HR+ Advanced Breast Cancer

20. MONALEESA-2 Safety Profile

21. Managing Treatment-Related Adverse Events from CDK Inhibitors

22. BOLERO-2 Everolimus + Exemestane vs Placebo + Exemestane

23. BOLERO-2 Most Common Grade 3/4 Adverse Events

24. SWISH Trial Dexamethasone-Based Mouthwash for Stomatitis

25. Management Issues With Everolimus

26. PALOMA-3 Palbociclib + Fulvestrant in Pre/Perimenopausal MBC

27. PALOMA-3 Safety Results

28. Educating our patients

29. Managing Adherence to Oral Therapy

30. Specific Measures To Manage Patients

31. Concluding Remarks

32. Abbreviations

33. Abbreviations (cont)